Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz
In 2025, the immuno-oncology market in India was estimated to be around ₹3,900 crore and predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.thehindu.com — the content belongs to The Hindu - Sci-Tech.
